Drug Trial Radar · NCT04775485
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
141
Planned (sponsor's estimate)
Start
Apr 22, 2021
Primary completion
May 31, 2027
Study completion May 31, 2027
Sponsor
- Lead sponsor
- Day One Biopharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Pacific Pediatric Neuro-Oncology Consortium
- First posted
- Mar 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months, up to 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified through molecular assays as routinely performed at Clinical Laboratory Improvement Amendments (CLIA) of 1988 or other similarly certified laboratories prior to enrollment into any of the arms. The study will consist of a screening period, a treatment period, a long-term extension phase, end of treatment (EOT) visit(s), a safety follow-up visit, and long-term follow-up assessments.
Conditions
- Low-grade Glioma
- Advanced Solid Tumor
Interventions
TovorafenibDrug
Tovorafenib is an oral Type II RAF kinase inhibitor available in 100 mg immediate-release tablet or 25 mg/milliliter (mL) powder for reconstitution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Arm 1: Overall response rateTime frame: Up to 48 months
- Arm 2: Number of participants reporting adverse eventsTime frame: Up to 48 months
- Arm 2: Number of participants with clinically significant changes in clinical chemistry parametersTime frame: Up to 48 months
- Arm 2: Number of participants with clinically significant changes in hematology parametersTime frame: Up to 48 months
- Arm 3: Overall response rateTime frame: Up to 48 months
Locations
35 sites in 11 countries. Site status is shown where the registry gives one.
UCSF Benioff Children's Hospital
San Francisco, California · Recruiting
Children's National Medical Center
Washington D.C., District of Columbia · Recruiting
Lurie Children's Hospital of Chicago
Chicago, Illinois · Recruiting
Johns Hopkins Hospital
Baltimore, Maryland · Terminated
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
CS Mott Children's Hospital
Ann Arbor, Michigan · Recruiting
St. Louis Children's Hospital
St Louis, Missouri · Recruiting
NYU Langone Health
New York, New York · Recruiting
Duke Cancer Center
Durham, North Carolina · Recruiting
Doernbecher Children's Hospital Oregon & Health Science University
Portland, Oregon · Terminated
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania · Recruiting
Texas Children's Hospital
Houston, Texas · Recruiting
University of Utah
Salt Lake City, Utah · Recruiting
Seattle Children's Hospital
Seattle, Washington · Recruiting
Queensland Children's Hospital
Brisbane, Australia · Recruiting
Royal Children's Hospital
Parkville, Australia · Recruiting
Perth Children's Hospital
Perth, Australia · Recruiting
Sydney Children's Hospital
Randwick, Australia · Recruiting
The Children's Hospital at Westmead
Westmead, Australia · Recruiting
Centre Hospitalier Universitaire Ste-Justine
Montreal, Quebec, Canada · Recruiting
Montreal Children's Hospital
Montreal, Quebec, Canada · Recruiting
Centre Mère-Enfant Soleil du CHU
Québec, Quebec, Canada · Recruiting
Rigshospitalet
Copenhagen, Denmark · Recruiting
Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Otto-Heubner-Centrum für Kinder
Berlin, Germany · Recruiting
Hopp-Kindertumorzentrum Heidelberg (KiTZ), KiTZ Clinical Trial Unit (ZIPO)
Heidelberg, Germany · Recruiting
Rambam Health Care Campus
Haifa, Israel · Recruiting
Schneider Children's Medical Center of Israel
Petah Tikva, Israel · Recruiting
The Chaim Sheba Medical Center
Ramat Gan, Israel · Recruiting
Princess Maxima Center for Pediatric Oncology
Utrecht, Netherlands · Recruiting
KK Women's and Children's Hospital
Singapore, Singapore · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Severance Hospital - Yonsei University
Seoul, South Korea · Recruiting
Universitäts-Kinderspital Zürich - Eleonorenstiftung
Zurich, Switzerland · Recruiting
UCL Great Ormond Street Institute of Child Health
London, United Kingdom · Recruiting
Newcastle University
Newcastle upon Tyne, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.